Design and optimization of novel formulations for Antibody -DrugConjugates(ADCs), biosimilars , monoclonal antibodies(mAbs), fusion proteins, glycoproteins, recombinant hormones, peptibodies, peptides, and cell&genetherapy(CGT) with a focus on stability, manufacturability, and patient convenience.
We develop formulation strategies for complex ADC molecules with a focus on maintaining the stability and integrity of the antibody, linker, and payload components. Our approach addresses aggregation, degradation, solubility, and product quality challenges associated with these highly sophisticated therapeutics.
We support the development of robust formulations for biosimilar products with a focus on physicochemical stability, product quality, and similarity to the reference biologic. Our formulation strategies are designed to support development from early characterization through scale-up and manufacturing.
We develop stable and optimized formulations for monoclonal antibodies across a range of concentrations and delivery requirements. Our work addresses aggregation, viscosity, particle formation, chemical degradation, and long-term stability to support patient-centric biologic products.
We design formulation approaches for complex fusion proteins while addressing challenges related to conformational stability, aggregation, proteolytic degradation, and interfacial stress. Our goal is to develop robust formulations suitable for both development and scalable manufacturing.
Our formulation expertise supports glycoprotein therapeutics where structural integrity and product quality are critical to biological activity. We investigate formulation and process conditions to minimize degradation, aggregation, and other stability-related changes during storage and handling.
We develop formulation strategies for recombinant hormones with emphasis on maintaining molecular integrity, biological activity, and stability throughout the product lifecycle. Formulation optimization can address sensitivity to temperature, interfaces, oxidation, aggregation, and other degradation pathways.
We address the unique formulation challenges of peptibodies, which combine peptide functionality with an antibody-based architecture. Our development strategies focus on stability, aggregation control, viscosity, molecular integrity, and delivery requirements for these multifunctional biologics.
We develop innovative formulations for therapeutic peptides with a focus on improving chemical and physical stability while maintaining biological activity. Our approaches can address challenges such as oxidation, deamidation, aggregation, adsorption, solubility, and delivery optimization.
We explore formulation and delivery strategies for emerging cell and gene therapy products, with particular attention to product stability, biological activity, storage, and administration requirements. Our multidisciplinary approach supports the development of innovative solutions for complex next-generation therapeutic modalities.
The successful development of a biologic therapy increasingly depends not only on the molecule, but also on how the medicine is delivered to the patient.
Zyconix Biologics brings together formulation science and drug-delivery expertise to support the development of drug-device combination products designed for reliable administration, improved patient convenience, and differentiated therapeutic delivery.
We provide science- and regulatory-based support for drug-device combination product development, from device selection through submission readiness.
Exploration and development of innovative delivery approaches that extend therapeutic reach, improve patient compliance, and reduce dosing frequency.
Comprehensive analytical support throughout development programmes — characterising protein structure, aggregation, stability, and product quality attributes.
We welcome collaboration with pharmaceutical companies, biotechnology organisations, academic institutions, and medical device innovators.